Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NSAIDs in neuroblastoma therapy.

John I Johnsen1, Magnus Lindskog, Frida Ponthan

  • 1Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institutet, Stockholm S-171-76, Sweden. john.inge.johnsen@kbh.ki.se

Cancer Letters
|June 25, 2005
PubMed
Summary

Nonsteroidal anti-inflammatory drugs (NSAIDs) targeting cyclooxygenase-2 (COX-2) show promise in treating neuroblastoma. Inhibiting COX-2 in neuroblastoma cells and tumors induces apoptosis and reduces growth, suggesting NSAIDs as a potential adjuvant therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surveillance adherence and clinical findings in children with confirmed or familial TP53 variants: the Swedish multicenter constitutional TP53 study (SWEP53).

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Drug delivery·2026
Same author

Ribosomal modifications are associated with mesenchymal fate selection in the neural crest lineage.

Nature communications·2026
Same author

Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving field.

Journal of internal medicine·2026
Same author

Immunobiological mechanisms of action of oncolytic peptides.

Journal for immunotherapy of cancer·2026
Same author

Systemic Immune Alterations in Paediatric Classical Hodgkin Lymphoma With CCL17 and MCP-4 as Diagnostic and Predictive Biomarkers.

EJHaem·2026

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Cyclooxygenases (COX) catalyze prostaglandin synthesis; COX-2 is upregulated in various epithelial cancers.
  • Neuroblastoma tumors and cell lines predominantly express high levels of COX-2, unlike normal adrenal medullas.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit COX activity.

Purpose of the Study:

  • To investigate the efficacy of cyclooxygenase (COX) inhibitors as a potential therapeutic strategy for neuroblastoma.
  • To explore the mechanisms of neuroblastoma cell death induced by COX inhibition.
  • To identify potential pharmacodynamic markers for monitoring neuroblastoma response to COX inhibition.

Main Methods:

  • Treatment of neuroblastoma cell lines and xenografts with various COX inhibitors (diclofenac, celecoxib).

Related Experiment Videos

  • Assessment of apoptosis via the intrinsic mitochondrial pathway.
  • In vitro studies involving arachidonic acid and diclofenac, with and without lipoxygenase inhibition.
  • Proton magnetic resonance spectroscopy (1H MRS) to analyze metabolic changes in treated neuroblastoma cells.

    • Main Results:

    • NSAID treatment induced caspase-dependent apoptosis in neuroblastoma cells.
    • Inhibition of neuroblastoma xenograft growth in vivo using dual and COX-2 specific inhibitors.
    • Synergistic cell death observed with combined arachidonic acid and diclofenac treatment, enhanced by lipoxygenase inhibition.
    • 1H MRS revealed polyunsaturated fatty acid accumulation and choline compound depletion in treated cells.

    Conclusions:

    • COX-2 inhibition effectively reduces neuroblastoma growth and induces apoptosis.
    • 1H MRS can serve as a pharmacodynamic marker for neuroblastoma response to COX inhibition.
    • NSAIDs represent a promising novel adjuvant therapy for pediatric neuroblastoma.